Stifel raises Tandem Diabetes Care to buy from hold, lifts target price to $26 from $22
TNDM•Stifel raised its rating on Tandem Diabetes Care to buy from hold and increased its target price to $26 from $22.
Related News

Ducommun CFO participates in Goldman Sachs Industrials and Materials Conference
DCO•

US research roundup: Calumet, Disney, Nvidia
NVDA•

CIBC sets final terms for up to GBP 1 million preference share-linked note offering
CM•

LifeMD target price cut to $6 from $9 by H.C. Wainwright
LFMD•

Meridian Holdings subsidiary Expanse Studios signs distribution deal with Playtech
MRDN•